Michael J McKay1, Su Kak Goh2, Jeremy N McKay3, Michael Chao4, Timothy M McKay5. 1. University of Sydney, Department of Medicine, Camperdown, 2050 NSW, Australia. 2. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 3. Monash University, Clayton, 3260 VIC, Australia. 4. Genesis Cancer Care, Melbourne, 3001 VIC, Australia. 5. Deakin University, Burwood, 3125 VIC, Australia.
Abstract
BACKGROUND: Clinical radiosensitivity is a significant impediment to tumour control and cure, in that it restricts the total doses which can safely be delivered to the whole radiotherapy population, within the tissue tolerance of potentially radiosensitive (RS) individuals. Understanding its causes could lead to personalization of radiotherapy. METHODS: We screened tissues from a unique bank of RS cancer patients for expression defects in major DNA double-strand break repair proteins, using Western blot analysis and subsequently reverse-transcriptase polymerase chain reaction and pulsed-field gel electrophoresis. RESULTS: We hypothesized that abnormalities in expression of these proteins may explain the radiosensitivity of some of our cancer patients. The cells from one patient showed a reproducibly consistent expression reduction in two complex-forming DNA double-strand break repair protein components (DNA Ligase IV and XRCC4). We also showed a corresponding reduction in both gene products at the mRNA level. Additionally, the mRNA inducibility by ionizing radiation was increased for one of the proteins in the patient's cells. We confirmed the likely functional significance of the non-homologous end-joining (NHEJ) expression abnormalities with a DNA double strand break (DNA DSB) repair assay. CONCLUSIONS: We have identified a novel biological phenotype linked to clinical radiosensitivity. This is important in that very few molecular defects are known in human radiotherapy subjects. Such knowledge may contribute to the understanding of radiation response mechanisms in cancer patients and to personalization of radiotherapy.
BACKGROUND: Clinical radiosensitivity is a significant impediment to tumour control and cure, in that it restricts the total doses which can safely be delivered to the whole radiotherapy population, within the tissue tolerance of potentially radiosensitive (RS) individuals. Understanding its causes could lead to personalization of radiotherapy. METHODS: We screened tissues from a unique bank of RS cancerpatients for expression defects in major DNA double-strand break repair proteins, using Western blot analysis and subsequently reverse-transcriptase polymerase chain reaction and pulsed-field gel electrophoresis. RESULTS: We hypothesized that abnormalities in expression of these proteins may explain the radiosensitivity of some of our cancerpatients. The cells from one patient showed a reproducibly consistent expression reduction in two complex-forming DNA double-strand break repair protein components (DNA Ligase IV and XRCC4). We also showed a corresponding reduction in both gene products at the mRNA level. Additionally, the mRNA inducibility by ionizing radiation was increased for one of the proteins in the patient's cells. We confirmed the likely functional significance of the non-homologous end-joining (NHEJ) expression abnormalities with a DNA double strand break (DNA DSB) repair assay. CONCLUSIONS: We have identified a novel biological phenotype linked to clinical radiosensitivity. This is important in that very few molecular defects are known in human radiotherapy subjects. Such knowledge may contribute to the understanding of radiation response mechanisms in cancerpatients and to personalization of radiotherapy.
Entities:
Keywords:
DNA double strand break (DNA DSB); Non-homologous end-joining (NHEJ); radiosensitivity cancer
Authors: E Riballo; S E Critchlow; S H Teo; A J Doherty; A Priestley; B Broughton; B Kysela; H Beamish; N Plowman; C F Arlett; A R Lehmann; S P Jackson; P A Jeggo Journal: Curr Biol Date: 1999-07-01 Impact factor: 10.834
Authors: Catherine T Yan; Dhruv Kaushal; Michael Murphy; Yu Zhang; Abhishek Datta; Changzhong Chen; Brianna Monroe; Gustavo Mostoslavsky; Kristen Coakley; Yijie Gao; Kevin D Mills; Alex P Fazeli; Suprawee Tepsuporn; Giles Hall; Richard Mulligan; Edward Fox; Roderick Bronson; Umberto De Girolami; Charles Lee; Frederick W Alt Journal: Proc Natl Acad Sci U S A Date: 2006-05-02 Impact factor: 11.205
Authors: Michael J McKay; Nimali Withana; Deborah S Davey; Danial Bishop; Michael Chao; Carl N Sprung Journal: Asia Pac J Clin Oncol Date: 2010-12-22 Impact factor: 2.601
Authors: Zhiming Fang; Sergei Kozlov; Michael J McKay; Rick Woods; Geoff Birrell; Carl N Sprung; Dédée F Murrell; Kiran Wangoo; Linda Teng; John H Kearsley; Martin F Lavin; Peter H Graham; Raymond A Clarke Journal: Genome Integr Date: 2010-06-24
Authors: Gillian C Barnett; Charlotte E Coles; Rebecca M Elliott; Caroline Baynes; Craig Luccarini; Don Conroy; Jennifer S Wilkinson; Jonathan Tyrer; Vivek Misra; Radka Platte; Sarah L Gulliford; Matthew R Sydes; Emma Hall; Søren M Bentzen; David P Dearnaley; Neil G Burnet; Paul D P Pharoah; Alison M Dunning; Catharine M L West Journal: Lancet Oncol Date: 2011-12-12 Impact factor: 41.316